Medicenna is a clinical stage immunotherapy company driven by a strong mission to design life-changing therapies that will revolutionize healthcare. Leveraging their world-class cytokine biology expertise, Medicenna engineers novel and proprietary interleukins known as Superkines. With their Superkine Platform, they are able to modulate, fine-tune, or amplify the immune system to combat the most challenging diseases, including a wide range of cancers with substantial unmet needs.

Medicenna values tackling difficult challenges, focusing on groundbreaking science, challenging the status quo, recognizing the importance of time, and believing in better patient outcomes. They are dedicated to creating a healthier future for patients facing tough diseases by continuously improving and staying ahead of the curve with the power of interleukins. The name Medicenna itself reflects their commitment to evidence-based medicine and draws inspiration from Avicenna, the father of evidence-based medicine and a distinguished medical scholar throughout history.

With Medicenna's leadership and innovative platform, they strive to transform medicine through strong evidence, critical thinking, and perseverance